Aug 12, 2025 • Benzinga
NEUTRAL
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma ( NASDAQ:AMPH ) , Fresenius Medical Care ( NYSE:FMS )
FDA approves Amphastar's generic Venofer, eyeing $80 million-$100 million in sales. Amphastar shares were boosted by an analyst upgrade to buy with a $36 target. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → On Monday, the U.S.
Aug 08, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Are Investors Undervaluing Amphastar Pharmaceuticals ( AMPH ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Aug 07, 2025 • Motley Fool
SOMEWHAT-BULLISH
Amphastar ( AMPH ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 9:00 p.m. ETChief Executive Officer - Dan DischnerContinue reading ...
Aug 07, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Amphastar Pharmaceuticals ( AMPH ) Q2 Earnings and Revenues Beat Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Zacks Commentary
NEUTRAL
BridgeBio Pharma ( BBIO ) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -14.46% and +14.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 04, 2025 • Zacks Commentary
NEUTRAL
Will Taysha Gene Therapies, Inc. ( TSHA ) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.